ENTRY       D12413                      Drug
NAME        Glenzocimab (USAN/INN)
FORMULA     C2126H3290N574O683S15
EXACT_MASS  48269.6166
MOL_WEIGHT  48299.2818
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYNMHWVRQA PGQGLEWMGG IYPGNGDTSY
            NQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARGT VVGDWYFDVW GQGTLVTVSS
            ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
            GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTH
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCRSSQSLE NSNGNTYLNW YQQKPGKAPK LLIYRVSNRF
            SGVPSRFSGS GSGTDFTFTI SSLQPEDIAT YYCLQLTHVP WTFGQGTKVE ITRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H147-H203, H223-L219, L23-L93, L139-L199)
  TYPE      Peptide
EFFICACY    Immunomodulator, Anti-platetet glycoprotein VI antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of the acute phase of ischemic stroke
TARGET      GP6 [HSA:51206] [KO:K06264]
  PATHWAY   hsa04512(51206)  ECM-receptor interaction
            hsa04611(51206)  Platelet activation
BRITE       Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                GP6
                 D12413  Glenzocimab (USAN/INN)
DBLINKS     CAS: 2101829-58-5
///
